Fennec Pharmaceuticals CMO Sayad Sargis Receives 168 Shares

What Happened

• Sayad Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals, recorded an acquisition of 168 shares on 2026-06-30. The shares were reported at $0.00 per share (total reported cash consideration $0) — this reflects release of restriction/vesting rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (appears timely).
• Type: Award/Grant/Release of restricted shares (SEC transaction code A).
• Shares acquired: 168; reported price: $0.00; total cash paid: $0.
• Footnote: "Represents shares released from restriction from shares awarded 3/28/2025."
• Post-transaction holdings: Not disclosed in the provided filing extract.

Context

• This was a restricted-share release (vesting/award fulfillment). Such transactions are typically the fulfillment of prior compensation awards and do not represent an open-market buy or sale by the insider.
• No indication in the provided filing that this involves a 10% owner, a gift, or a 10b5-1 plan; information is limited to the vesting/release event.